Background: Acute myeloid leukemia
is a heterogeneous hematologic malignancy associated with gene mutations,
chromosomal rearrangements, deregulation of gene expression and epigenetic
modifications.Thetreatment outcome ofAMLis highly variable
signifying the heterogeneous nature of the disease. Aim of the Study: Toevaluate miRNA-155 expression
level as a prognostic marker for adult patients with acute myeloid leukemia. Patients
and Methods: 101 subjects were included in this study. They were classified
into 2 groups, patient group (61 adult patients with newly diagnosed acute
myeloid leukemia) and control group (40 apparently healthy adult subjects).miRNA-155 expression
was assessed using real time PCR using QIAGEN, miScript, QuantiTect and Rotor-isc (QIAGEN
Group) PAXgene (pre AnalytixGmbh). Samples were either peripheral blood or bone
marrow aspiration sample. Results: Roc curve detected 2.85 as best fit
value of miRNA-155 for discriminating patients from healthy controls with
sensitivity 92.3%, specificity 88.5%, AUC 0.98 and CI (0.96 - 0.99) (p < 0.001).
The 75thpercentile value of the patient group was taken as prognostic cut off value with a value <
9.8 as low miRNA-155 and a value ≥ 9.8 as high miRNA-155.The expression level
of miRNA-155 was significantly higher in AML patients than in controls (p =
0.002). Patients with high miRNA expression had a significantly higher white blood cells count (p = 0.002),
bone marrow blasts (p = 0.006) and peripheral blood blasts (p = 0.006) compared
to patients with low miRNA-155 expression.Patients with poor cytogentics had a significantly
higher level of miRNA-155 expression compared to patients with favorable
cytogentics (p = 0.007). The complete remission rate was significantly higher
in patients with low miRNA-155 expression compared to those with high
Tili, E., Michaille, J.J., Wernicke, D., et al. (2011) Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer. Proceedings of the National Academy of Sciences of the United States of America, 108, 4908-4913.
Costinean, S., Sandhu, S.K., Pedersen, I.M., et al. (2009) Src Homology 2 Domain-Containing Inositol-5-Phosphatase and CCAAT Enhancer-Binding Protein β Are Targeted by miR-155 in B Cells of Eμ-MiR-155 Transgenic Mice. Blood, 114, 1374-1382. https://doi.org/10.1182/blood-2009-05-220814
Van Roosbroeck, K., Fanini, F., Setoyama, T., Ivan, C., Rodriguez-Aguayo, C., Fuentes-Mattei, E., et al. (2017) Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 23, 2891-2904.
Tang, L., Peng, Y.-Z., Li, C.-G., Jiang, H.-W., Mei, H. and Hu, Y. (2019) Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-Analysis. Journal of Cancer, 10, 654-664.
Babar, I.A., Cheng, C.J., Booth, C.J., Liang, X., Weidhaas, J.B., Saltzman, W.M. and Slack, F.J. (2012) Nanoparticle-Based Therapy in an in Vivo microRNA-155 (miR-155)-Dependent Mouse Model of Lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 109, E1695-E1704.
Ramamurthy, R., Hughes, M., Morris, V., Bolouri, H., et al. (2016): miR-155 Expression and Correlation with Clinical Outcome in Pediatric AML: A Report from Children’s Oncology Group. Pediatric Blood & Cancer, 63, 2096-2103.
Xu, L.-H., Guo, Y., Cen, J.N., Yan, W.-Y., He, H.L., et al. (2015) Overexpressed miR-155 Is Associated with Initial Presentation and Poor Outcome in Chinese Pediatric Acute Myeloid Leukemia. European Review for Medical and Pharmacological Sciences, 19, 4841-4850.
O’Connell, R.M., Rao, D.S., Chaudhuri, A.A., et al. (2008) Sustained Expression of MicroRNA-155 in Hematopoietic Stem Cells Causes a Myeloproliferative Disorder. The Journal of Experimental Medicine, 205, 585-594.
Chuang, M.K., Chiu, Y.-C., Chou, W.-C., Hou, H.-A., Chuang, E.Y. and Tien, H.-F. (2015) A 3-MicroRNA Scoring System for Prognostication in de Novo Acute Myeloid Leukemia Patients. Leukemia, 29, 1051-1059.